TytoCare Names Adam Pellegrini as CEO and Closes $25M+ Growth Round to Scale AI-First Clinical Enablement Platform

TytoCare, a pioneer in remote physical examination technology, has successfully closed a $25 million growth round led by Insight Partners, with participation from notable investors including HOOP, OliveTree, OrbiMed, Qumra Capital, and Qualcomm Ventures. The funding, announced on July 15, 2026, is aimed at expanding TytoCare's AI-first clinical enablement platform, which integrates FDA-cleared medical devices and AI-powered algorithms to enhance virtual primary care delivery for patients with chronic and complex diseases.

Under the leadership of newly appointed CEO Adam Pellegrini, TytoCare is repositioning itself to address the significant gap between in-person clinical rigor and virtual care delivery. Pellegrini, who brings over two decades of experience in digital health and large-scale clinical programs, will spearhead the company's efforts to embed its remote examination platform and AI algorithms directly into integrated care pathways. This strategic focus includes enhancing care for patients with conditions such as congestive heart failure, chronic obstructive pulmonary disease, and oncology treatment monitoring.

The recent funding round reflects strong institutional confidence in TytoCare's market position and the growing demand for AI-enabled remote diagnostics. The oversubscribed financing will support the expansion of the company's AI clinical algorithms pipeline, deepen partnerships with payers and health systems, and accelerate go-to-market strategies targeting high-acuity chronic disease populations. By combining a handheld examination device with AI capabilities, TytoCare aims to provide clinicians with the tools necessary to conduct comprehensive remote physical exams, thereby improving diagnostic confidence and care outcomes.

TytoCare's innovative approach addresses a critical need in the healthcare sector, particularly as health systems increasingly seek to extend clinical care into patients' homes. The integration of AI-powered diagnostic algorithms with FDA-cleared examination devices represents a significant advancement in telehealth, offering a level of diagnostic fidelity that has historically been challenging to achieve in virtual settings. This model not only enhances patient care but also positions TytoCare as a key partner for health systems looking to implement effective chronic disease management strategies.

Looking ahead, the implications of this funding and TytoCare's strategic initiatives are substantial for the broader healthcare market. As the demand for remote care solutions continues to rise, particularly in the wake of the COVID-19 pandemic, companies that can deliver high-quality, clinically validated remote care will likely gain a competitive edge. TytoCare's focus on integrating advanced technology into care workflows may set a new standard for virtual primary care, ultimately reshaping how healthcare is delivered to complex patient populations.